7:29 AM
 | 
Jun 29, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tecentriq meets endpoints in Phase III for extensive-stage SCLC

Roche (SIX:ROG; OTCQX:RHHBY) said first-line treatment with Tecentriq atezolizumab plus chemotherapy met the co-primary endpoints of improving overall survival (OS) and progression-free survival (PFS) compared with chemotherapy alone in the Phase III IMpower133 trial to treat extensive-stage small cell lung cancer (SCLC). The company plans submit the data to...

Read the full 221 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >